4 completed, 2 recruiting, 1 terminated, 1 withdrawn. 3 Phase 1, 3 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Withdrawn 1 |
Follow ferumoxides: new trials by email Literature Review of ferumoxides trials Research Report on ferumoxides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis. Safety assessment of Ferumoxytol., Assessment of the diagnostic value of Ferumoxytol for MR angiography. - Atherosclerosis | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 100 | 2024-08-12 | 2024-08-13 | |
| Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients Superparamagnetic Iron Oxide, Technetium99 - Breast Cancer, Sentinel Lymph Node | Phase 2 | Recruiting | Vastra Gotaland Region | 220 | 2023-01-01 | 2024-01-26 |
| Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide Superparamagnetic Iron Oxide - Breast Cancer, Sentinel Lymph Node | Phase 1 / Phase 2 | Completed | Vastra Gotaland Region | 50 | 2021-11-01 | 2025-03-28 |
| Ferumoxytol-enhanced Imaging of Osteomyelitis Ferumoxides 11.2Mg Solution for Injection - Osteomyelitis | Phase 1 | Completed | University of New Mexico | 12 | 2014-02-12 | 2023-07-25 |
| Inflammatory Cell Trafficking After Myocardial Infarction Infusion of investigational product, Cardiac magnetic resonance imaging - Myocardial Infarction, Inflammation | Not applicable | Withdrawn | University of Edinburgh | 2010-01-01 | 2024-05-02 | |
| Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran Ferucarbotran (Resovist) - Acute Myocardial Infarction | Phase 2 / Phase 3 | Completed | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) | 20 | 2009-03-01 | 2014-11-07 |
| Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging ferucarbotran (iron-based MRI contrast agent), Islet transplantation, Magnetic resonance imaging - Type 1 Diabetes Mellitus | Phase 1 | Terminated | University Hospital, Geneva | 5 | 2005-06-01 | 2014-12-02 |
| Identification of Hepatic Lesions Resovist (BAY86-4884, SH U 555 A) - Hepatic Neoplasms | Phase 3 | Completed | Bayer | 218 | 2001-04-01 | 2009-05-18 |
Breast Neoplasms (2) · Atherosclerosis (1) · Diabetes Mellitus, Type 1 (1) · Inflammation (1) · Liver Neoplasms (1) · Myocardial Infarction (1) · Osteomyelitis (1)
Vastra Gotaland Region (2) · Bayer (1) · Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · University Hospital, Geneva (1) · University of Edinburgh (1) · University of New Mexico (1)
Sweden (2) · China (1) · Germany (1) · Italy (1) · Switzerland (1) · United Kingdom (1) · United States (1)
David E Newby, MD, PhD (1) · Laurel Sillerud, PhD (1) · Roger Olofsson Bagge, MD, PhD (1) · Thierry Berney, MD, MSc (1) · Udo Sechtem, MD (1)